Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Intern Med
; 59(4): 569-572, 2020 Feb 15.
Article
in En
| MEDLINE
| ID: mdl-31666468
The patient was a 73-year-old woman with lung adenocarcinoma and systemic lupus erythematosus (SLE) who was treated with pembrolizumab. After six cycles of pembrolizumab, she developed symptoms suggestive of neuropsychiatric SLE, such as resting tremor, confusional state, depression, mood disorder, and anxiety disorder. In addition, her cerebrospinal fluid level of interleukin-6 was elevated. Her symptoms resolved one month after the discontinuation of pembrolizumab. This is the first report of neuropsychiatric symptoms in a patient with lung cancer and SLE on immune checkpoint blockade therapy.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Mood Disorders
/
Antibodies, Monoclonal, Humanized
/
Antineoplastic Agents, Immunological
/
Adenocarcinoma of Lung
/
Lupus Erythematosus, Systemic
Limits:
Aged
/
Female
/
Humans
Language:
En
Journal:
Intern Med
Journal subject:
MEDICINA INTERNA
Year:
2020
Document type:
Article
Affiliation country:
Japan
Country of publication:
Japan